The Eye Scan for Alzheimer’s Early Insight
An Early Warning System for Alzheimer’s
A simple eye scan that patients can take right in their doctor’s office empowers physicians and patients to take charge of their cognitive health.
The key to interventional therapy for Alzheimer’s is an “early warning system” for the disease, before treatment options become limited. Cognoptix has demonstrated successful early clinical results as the company develops its diagnostic platform – a laser eye scanning device combined with an eye ointment that binds to beta amyloid – a key Alzheimer’s-related protein. Amyloid deposits accumulates in the brain, but can also be detected and measured in the lens of the eye.
"Cognoptix: Pioneering the Early Detection of Alzheimer’s Disease"
Cognoptix was recently profiled by MedTech Outlook as one of the Top 10 Non-Invasive Device Solution Providers for 2020.
Alzheimer’s Disease has long been recognized as a growing diagnostic and therapeutic challenge – especially diagnosing the disease early when intervention could have a real impact. Unfortunately, current diagnostic methods are invasive, expensive, and complex, and are not yet widely available.
In this landscape, there is a significant unmet need for a highly accurate, safe, simple, non-invasive, and cost-effective test to aid in the early detection and diagnosis of Alzheimer’s disease.
To meet these needs, Cognoptix was co-founded by Dr. Lee Goldstein and Dr. Leo Chylack of the Brigham and Women’s Hospital in Boston. Together they developed an innovative system to detect beta amyloid proteins – a hallmark of Alzheimer’s disease – in the lens of the eye.
Alzheimer’s Disease is a growing challenge – especially diagnosing the disease early when intervention could have a real impact. Current diagnostic methods are invasive, expensive, and complex, and are not yet widely available.
There is a significant unmet need for a highly accurate, safe, simple, non-invasive, and cost-effective test for early detection and diagnosis of Alzheimer’s disease.
Cognoptix was co-founded by Dr. Lee Goldstein and Dr. Leo Chylack of the Brigham and Women’s Hospital in Boston. Together they developed an innovative system to detect beta amyloid proteins – a hallmark of Alzheimer’s disease – in the lens of the eye.
Pioneers in Alzheimer’s Diagnostics
Drs. Chylack and Goldstein and their research team discovered that they could detect beta amyloid aggregates in the lens of the eye and that those proteins could be measured and monitored with non-invasive tools, such as existing laser eye scanning technologies. Further research determined that suspect beta amyloid proteins could be detected in the eye prior to buildup of toxic plaques in the brains of genetically engineered Alzheimer’s mice. Cognoptix is currently developing combined optical scanning devices and diagnostic agents based on these discoveries for clinical, commercial and academic research use. The company is actively forming and seeking new strategic alliances with pharma partners and academic institutes, while preparing its diagnostic platform for clinical use.
News
Dr. Marwan Sabbagh Joins the Cognoptix Scientific Advisory Board
Cognoptix announced that Marwan Noel Sabbagh, MD has joined Cognoptix’ Scientific Advisory Board. Dr. Sabbagh will play a pivotal role in helping guide the strategic direction of the company to support the continued efforts of achieving FDA approval for the Sapphire II system.
A pioneer in creating and developing a simple, innovative, non-invasive eye scanning test to aid in the early detection and diagnosis of Alzheimer’s Disease: Cognoptix
Various healthcare researchers and companies are trying to innovate new methods to diagnose Alzheimer’s, but Cognoptix stands out from the rest with its Sapphire II system, detecting Alzheimer’s disease through a simple scan of the lens of the eye.
Cognoptix Appoints New Chief Medical Officer, Dr. Carl Sadowsky, MD, and Chief Financial Officer, Mike Kaswan, MBA, to Management Team
Cognoptix announced that Carl H. Sadowsky, MD, will serve as the company’s new Chief Medical Officer (CMO), and Mike Kaswan, MBA, will be Cognoptix’s Chief Financial Officer (CFO).
Cognoptix Announces Formation of a New Board of Directors
As another milestone of its Series R restart, recapitalization, and revitalization, the company named a new Board of Directors under President and CEO Susanne Wilke, Ph.D.
Cognoptix Investor Presentation
December 2021
“Cognoptix: Pioneering the Early Detection of Alzheimer’s Disease”
Cognoptix was recently profiled by MedTech Outlook as one of the Top 10 Non-Invasive Device Solution Providers for 2020.
“A pioneer in creating and developing a simple, innovative, non-invasive eye scanning test to aid in the early detection and diagnosis of Alzheimer’s Disease: Cognoptix”
Various healthcare researchers and companies are trying to innovate new methods to diagnose Alzheimer’s, but Cognoptix stands out from the rest with its Sapphire II system, detecting Alzheimer’s disease through a simple scan of the lens of the eye.